Clinical Trials Logo

Filter by:
NCT ID: NCT05138094 Recruiting - Neoplasm Metastasis Clinical Trials

LIVACOR Trial: Minimally Invasive LIVer And Simultaneous COlorectal Resection

Start date: August 6, 2021
Phase: N/A
Study type: Interventional

The LIVACOR - Trial is a European wide, randomized controlled, open-label, multicenter trial. Patients with synchronous colorectal liver metastases (CRLMs) and primary colorectal tumor are considered eligible and will be randomized between minimally invasive (MI) combined or staged colorectal resection (all colectomies, including high anterior resection) and liver resection of up to three segments.

NCT ID: NCT04891133 Recruiting - COVID-19 Clinical Trials

EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial

Start date: June 3, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

EU SolidAct is a randomized, multifactorial, adaptive platform trial for COVID-19 and emerging infectious diseases and pandemics. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to hospital with COVID-19. The platform is designed for running phase 2 and phase 3 trials, and with modular data capture (end point/safety data, biobanking, add-on studies) depending on the capacity of participating sites. The study consists of two parts with different primary end points depending on disease stage: EU SolidAct part A includes hospitalized patients with moderate disease, whereas EU SolidAct part B includes hospitalized patients with severe and critical disease.

NCT ID: NCT04848623 Recruiting - Chronic Disease Clinical Trials

Identification of Vocal Biomarkers to Monitor the Health of People With a Chronic Disease

CoLive Voice
Start date: June 26, 2021
Study type: Observational

The CoLive Voice research project aims to identify vocal biomarkers of severe conditions and frequent health symptoms. The project is based on digital technologies and statistical algorithms. This is an international anonymous survey where vocal recordings are collected simultaneously with large validated clinical and epidemiological data, in the context of various chronic diseases or frequent health symptoms in the general population.

NCT ID: NCT04792177 Recruiting - Sexual Dysfunction Clinical Trials

Internet-based Emotion Regulation Intervention for Sexual Health

Start date: May 5, 2021
Phase: N/A
Study type: Interventional

Introduction: Emotion regulation difficulties have been associated with mental disorders and sexual dysfunctions. Traditional face-to-face transdiagnostic emotion regulation interventions have shown positive results for emotional and personality disorders. Only recently have the effects of these interventions on sexual health started to be investigated. Internet-delivered psychological interventions have several advantages over face-to-face interventions, such as cost-effectiveness, accessibility and suitability for people who experience shame because of their stigmatized problematic behaviors and those who avoid seeking help. The aims of the SHER 2 study are: a) determine the efficacy of an Internet-based emotion regulation intervention for sexual health and sexual satisfaction, and; b) explore the effects of the intervention on (1) emotion regulation skills; (2) mental health; (3) sexual self-perception.

NCT ID: NCT04778176 Recruiting - Parkinson's Disease Clinical Trials

Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients

Start date: June 16, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether the DopaFuse System can reduce the fluctuation of plasma levodopa levels compared to participants' standard intermittent doses of oral LD/CD tablets (background treatment). It will also assess whether the system is safe, well tolerated, and can relieve motor symptoms.

NCT ID: NCT04694001 Not yet recruiting - Stroke Clinical Trials

Evaluation of the Use of the Atalante Exoskeleton in Patients Presenting an Hemiplegia Due to Cerebrovascular Accident

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

The INSPIRE study is interventional, European, prospective, open, multicentric, each patient being his/her own control. It is conducted to assess the safety and performance of the Atalante exoskeleton system in patients presenting an hemiplegia due to cerebrovascular accident. The primary endpoint is defined by the reported adverse events. The study will include 40 patients and takes place in six rehabilitation centers (4 in France, 1 in Luxembourg, 1 in Belgium).

NCT ID: NCT04648319 Recruiting - Cholangiocarcinoma Clinical Trials

A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma

Start date: April 15, 2021
Phase: Phase 2
Study type: Interventional

This is an Open-label, single-arm, multicenter Phase II pilot study to assess the efficacy and safety of BMS-936558 with stereotactic ablative radiation therapy after induction chemotherapy in cholangiocarcinoma.

NCT ID: NCT04625764 Recruiting - Clinical trials for Acute Coronary Syndrome

Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery

Start date: February 23, 2021
Phase: N/A
Study type: Interventional

The aim of CyTation is to demonstrate intra-operative removal of ticagrelor by CytoSorb® hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB, using platelet reactivity to adenosine diphosphate (ADP) as a pharmacodynamics surrogate measure of ticagrelor levels in blood.

NCT ID: NCT04604912 Recruiting - Allergy;Food Clinical Trials

Biomarkers in Food Allergy Diagnosis

Start date: September 1, 2017
Study type: Observational [Patient Registry]

Food allergy is a global burden, affecting patients, society as a whole and the economy. For most common food allergies, patients synthesize specific IgE-antibodies against harmless food proteins. Clinical phenotypes of food-allergic patients are highly diverse. Differences in medical symptoms (organs, severity, delay), threshold and cross-reactivity levels suggest variable underlying endotypes. The aim of this study is to identify phenotypic biomarkers for advanced stratification of food-allergic patients. Our study will consist of up to 50 participants (30 food-allergic, 20 tolerant), recruited in Luxembourg. Clinical samples will be collected before, during and after the event of a double-blind placebo-controlled food challenge for patients. Multi-omics analyses of blood (sera, peripheral blood mononuclear cell, basophils) and stool will allow a deeper understanding of the underlying immune mechanisms, including allergen metabolism aspects, as well as the functional gut microbiome. Deciphering these basic aspects during the present pilot study is expected to pave the way towards novel personalized medicine approaches for diagnosing and treating of food-allergic individuals. This study is a cooperation project between the Centre Hospitalier de Luxembourg (CHL), the Luxemburg Institute of Health (LIH), the University of Luxembourg and the Integrated Biobank of Luxemburg (IBBL).

NCT ID: NCT04380987 Recruiting - Covid19 Clinical Trials

Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis

Start date: May 4, 2020
Study type: Observational

Predi-COVID is a prospective cohort study composed of people positively tested for COVID-19 in Luxembourg, followed digitally for monitoring participants' health evolution and symptoms at home. Participants will be actively followed for 14 days from the time of confirmation of diagnosis, whether they are at the hospital or at home in isolation or quarantine. Short evaluations will be also performed at week 3 and week 4 and then monthly for a period up to 12 months to assess potential long term consequences of COVID-19. A subsample of 200 participants will be contacted to integrate complementary clinical data and collect samples. The study aims at identifying factors associated with the COVID-19 disease severity. COVID-19 patients with severity criteria will be compared to patients with mild disease managed at home. A deep phenotyping related to the symptoms of the disease as well as biosampling allowing for laboratory-based and computational analytics will be performed.